Subcutaneous Infliximab May Improve Convenience, Adherence, and Sustained Remission in IBD Care

Earlier this month, BioPharm International sat down with Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer of Celltrion, to discuss the company’s latest data on subcutaneous infliximab presented at Digestive Disease Week 2026. Dr. Jacob-Nara emphasized how subcutaneous infliximab could reshape inflammatory bowel disease treatment through greater patient convenience, dosing consistency, and sustained remission outcomes. The company says the self-administered formulation may reduce infusion-related burdens while supporting long-term efficacy in IBD management.

How could subcutaneous infliximab change treatment for patients with IBD?

At Digestive Disease Week (DDW) 2026, Celltrion highlighted the growing importance of patient-centered treatment strategies in inflammatory bowel disease (IBD), particularly as clinicians seek therapies that balance efficacy with convenience and long-term adherence.

Dr. Juby Jacob-Nara discussed the potential impact of subcutaneous infliximab-dyyb, describing the therapy as a significant advancement in the biologics landscape for IBD patients.

“Technically, it is a game changer for patients with IBD,” Jacob-Nara said.

According to Celltrion, the therapy represents the first subcutaneous infliximab available globally and in the United States, offering patients an alternative to intravenous infusion-based administration. The company emphasized that the self-injection format could improve flexibility, reduce travel and infusion-center time, and alleviate some of the psychological stress associated with hospital-based care.

Jacob-Nara noted that infusion centers often treat patients with severe illnesses, including cancer and terminal diseases, which can contribute to anxiety for individuals requiring chronic IBD treatment. By contrast, the self-administered pen injector allows patients to manage therapy in their own homes.

Beyond convenience, Celltrion also positioned the product as a potential operational advantage for healthcare systems. Subcutaneous administration may reduce staffing demands, infusion-chair utilization, and administrative costs associated with IV biologic delivery.

The company additionally highlighted the pharmacokinetic profile of subcutaneous infliximab, arguing that consistent dosing every two weeks may help maintain stable drug concentrations and support sustained remission.

“Number one, the product has to work and the patients have to get it and the drug has to stay consistent to sustain the efficacy,” Jacob-Nara said.

The discussion reflects broader industry interest in patient-centric biologic delivery models as companies increasingly compete on convenience, adherence, and real-world treatment experience in chronic inflammatory diseases.

Click here for more conference coverage.

About the speaker

Juby Jacob-Nara, MD, Senior VP, Chief Medical Officer, Celltrion USA

As a dedicated public health physician, Dr. Jacob-Nara brings more than 25 years of experience across sales, marketing, U.S. and global medical affairs, and clinical development across general, specialty, and precision medicines - including biologics, vaccines, and over-the-counter products. Driven by a strong commitment to patient value, she has contributed to the development and expanded access of specialty pharmaceuticals, vaccines, biologics, and direct-to-consumer medicines, with a focus on respiratory, autoimmune, infectious diseases, pain management, and women’s health. She has successfully contributed to more than 50 product launches, including vaccines in the U.S. and globally.